SPA
CRBP icon

Sherbrooke Park Advisers’s Corbus Pharmaceuticals CRBP Stock Holding History

Sherbrooke Park Advisers’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$125K Buy
+15,410
New +$190K 0.32% 117

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sherbrooke Park Advisers's CRBP Position: Q4 2025 in Review

Sherbrooke Park Advisers opened a new position in Corbus Pharmaceuticals (CRBP) in Q4 2025: 15,410 shares worth $125K. The stake represents 0.32% of the portfolio and ranks #117 among its holdings.

100 funds tracked by Wall St. Rank hold CRBP as of Q4 2025.

  • Sherbrooke Park Advisers held 15,410 shares of Corbus Pharmaceuticals worth $125K as of Q4 2025.
  • Corbus Pharmaceuticals was a new Sherbrooke Park Advisers position in Q4 2025.
  • Corbus Pharmaceuticals made up 0.32% of Sherbrooke Park Advisers's portfolio in Q4 2025, its #117 holding.
  • 100 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.